2025财年澳洲股票基金排行榜出炉 前五名收益率均超20%

人力资源和投资咨询公司美世（Mercer）发布的2025财年澳洲股票基金回报率排行榜显示，Chester Opportunities Fund以25.4%的回报率荣登榜首，前5名的回报率均超过20%，其中4只为可持续基金。

Bowen Coking Coal (ASX: BCB) Hits FY25 Output Target Early, Seeks Funding in Trading Halt

While The company confirmed it had achieved its full-year FY25 run-of-mine (ROM) coal production and sales guidance , Bowen’s share price declined sharply prior to the trading halt, closing at A$0.096 on 23June, with the company’s market capitalisation falling at about A$10 million — a sharp contrast to the hundreds of millions it was valued at during the COVID-era peak.

US Market Watch | Dow Eyes 45,000 Amid Tentative June Rebound

Following a volatile correction earlier this year, US equities have staged a strong comeback since mid-April. The Dow, Nasdaq, and S&P 500 all posted impressive gains in May—among the best monthly performances in years.

Adriatic Metals回应媒体收购传闻 证实正与Dundee Precious Metals洽谈潜在收购事项

Adriatic Metals plc（LSE: ADT1；ASX: ADT）上周（5月21日）发布公告，证实公司正在与加拿大矿业公司Dundee Precious Metals Inc.进行初步洽谈，探讨后者可能对Adriatic发起收购的可能性。

【异动股】银矿生产商Adriatic Metals (ASX:ADT)回应媒体收购传闻 股价大涨25%

Adriatic Metals Plc (ASX股票代码:ADT)股价异动，周三飙涨25.27%。澳华财经在线数据库显示，ADT最新价4.71澳元，已发行股本3.45亿股，市值16.3亿澳元。截止一季度末公司账面现金结余7592万美元。

Zip Co (ASX: ZIP) Rebounds Sharply — Is the Momentum Sustainable?

Zip Co Limited (ASX: ZIP) shares have staged a strong rebound, driven by improved financial performance and renewed investor interest. The stock remains high-beta and volatile, with market attention focusing on its turnaround potential.

ImpediMed (ASX: IPD) Reports Record Q3 Performance; Commercial Momentum Builds and Shares Rebound

5 May 2025 | ACB News – Sydney，ImpediMed Limited (ASX: IPD), a leading Australian medical technology company, has reported record results for the third quarter of FY2025, ended 31 March. Key financial metrics reached new highs as the company continues to scale deployment of its SOZO® digital health platform in the U.S.

ImpediMed (ASX: IPD) Delivers Record Q3 Results; Shares Rebound Last Week with Increasing Trading Volume

ImpediMed Limited (ASX: IPD) has reported record financial results for Q3 FY25, with revenue reaching A$3.4 million (+28% YoY), cash receipts at A$4.1 million, and ARR rising to A$13.7 million (+27% YoY). Total Contracted Value (TCV) hit A$4.9 million, up 53% from the previous quarter.